Fairvalue-Calculator Fairvalue-Calculator
EN DE

Pharma Mar, S.A (PHMMF) Fair Value & Analysis

Healthcare · US · Market cap $1.4B

Price$79.49
Fair Value$50.84
Upside-36.0%
Quality95/100
Evidence: High Range $38.13 – $142.14

Fair value as of: Jun 24, 2026

Analysis

Pharma Mar, S.A (PHMMF) currently trades at $79.49, while our model-based Fair Value estimate is $50.84 — implying the stock looks roughly 36.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer; Zepzelca, a synthetic compound designed to treat small lung cancer cells; and Aplidin, that is extracted from the ascidian Aplidium albicans to treat patients with multiple myeloma. It also develops LAGOON, which is in Phase III clinical trial for the treatment of small cell lung cancer; SaLuDo, which is in Phase III trial to treat patients with metastatic leiomyosarcoma; as well as PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical tri…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Pharma Mar, S.A (PHMMF) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $50.84 versus a price of $79.49 — about −36% (overvalued). Model-based estimate, not financial advice.
What is the fair value of PHMMF?
Our 21-model fair value for Pharma Mar, S.A is $50.84 (as of Jun 24, 2026), built from audited fundamentals. The current price is $79.49.
What is the quality score of PHMMF?
Pharma Mar, S.A has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.